{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126223","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.903235+00:00","generated_at":"2026-05-15T08:51:10.049127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3","bullets":["Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.","Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; Phase 2 for adjunctive MDD planned early 2027.","September 2025 IPO raised $327.8M (21.85M shares at $15); February 2026 private placement added $100M.","Cash and investments $295.2M at Dec 31, 2025; with private placement, runway into Q2 2029.","Q4 2025 net loss $11.5M ($5.1M Q4 2024); full-year net loss $25.2M ($63.1M 2024); R&D expenses declined YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126223","json":"https://secwatch.observer/filing/0001193125-26-126223.json","markdown":"https://secwatch.observer/filing/0001193125-26-126223.md","text":"https://secwatch.observer/filing/0001193125-26-126223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/0001193125-26-126223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/d129775d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:51:10.049127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cfe5e88e6e293cf599795576a4a7e85f47be120","claim":"LB PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"On March 26, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/0001193125-26-126223-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}